Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390370 | 0.80 | KMT2A (0.50) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL2171267 | 0.78 | ALDH1A1 (0.42) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL28264880 | 0.78 | MEN1 (0.34) | KMT2AMEN1ALDH1A1TSHRPOLB | |
| SCHEMBL22870271 | 0.78 | GAA (0.38) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL6942194 | 0.77 | KMT2A (0.59) | KMT2AMEN1APEX1MCL1GPR35 | |
| SCHEMBL6690917 | 0.77 | CYP1A2 (0.39) | KMT2AMEN1MCL1GPR35ALDH1A1 | |
| SCHEMBL7376159 | 0.77 | KMT2A (0.59) | KMT2AMEN1APEX1MCL1GPR35 | |
| SCHEMBL28443819 | 0.76 | KMT2A (0.57) | KMT2AMEN1APEX1MCL1GPR35 | |
| SCHEMBL15349677 | 0.76 | KMT2A (0.57) | KMT2AMEN1APEX1MCL1GPR35 | |
| SCHEMBL8978501 | 0.76 | GPR35 (0.44) | KMT2AMEN1GPR35CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023110138-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| EP-4192813-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023275336-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| EP-3490549-A1 | DERMATOLOGICAL FORMULATIONS OF 2-(2-ETHOXY-2-OXOETHYL)(METHYL)AMINO-2-OXOETHYL 5-(TETRADECYLOXY)FURAN-2-CARBOXYLATE | Dermira, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018022797-A1 | DERMATOLOGICAL FORMULATIONS OF 2-(2-ETHOXY-2-OXOETHYL)(METHYL)AMINO-2-OXOETHYL 5-(TETRADECYLOXY)FURAN-2-CARBOXYLATE | DERMIRA INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20180028487-A1 | DERMATOLOGICAL FORMULATIONS OF 2-(2-ETHOXY-2-OXOETHYL)(METHYL)AMINO-2-OXOETHYL 5-(TETRADECYLOXY)FURAN-2-CARBOXYLATE | DERMIRA, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20090291915-A1 | Silicon Compounds and Their Use | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| CN-101080413-A | Silicon compounds and their use | TAKEDA CAMBRIDGE LTD (GB) | 2007-11-28 | — | — | CN | disclosed |
| EP-1824862-A1 | SILICON COMPOUNDS AND THEIR USE | Takeda Cambridge Limited (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006064263-A1 | SILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| EP-1487827-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| CN-1507442-A | Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors | — | 2004-06-23 | — | — | CN | disclosed |
| WO-2003082862-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028487-A1 | DERMATOLOGICAL FORMULATIONS OF 2-(2-ETHOXY-2-OXOETHYL)(METHYL)AMINO-2-OXOETHYL 5-(TETRADECYLOXY)FURAN-2-CARBOXYLATE | CUTA, CYP1A2, DPM1 | KMT2A 339/4885MEN1 3030/4885APEX1 3615/4885 |
| US-20090291915-A1 | Silicon Compounds and Their Use | SOST, SIK2, SIK3 | KMT2A 600/4885MEN1 88/4885APEX1 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.